Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2014070> ?p ?o }
Showing triples 1 to 33 of
33
with 100 triples per page.
- Q2014070 subject Q52376.
- Q2014070 subject Q8431759.
- Q2014070 abstract "Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015, but as of early 2016 there was no report of any application. In 2014 Cowen and Co predicted odanacatib will generate a billion USD per year in sales by 2020.This drug was developed at Merck Frosst in Montreal.".
- Q2014070 atcPrefix "none".
- Q2014070 casNumber "603139-19-1".
- Q2014070 fdaUniiCode "N673F6W2VH".
- Q2014070 iupacName "N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-(L)-leucinamide".
- Q2014070 pubchem "10152654".
- Q2014070 thumbnail Odanacatib_Structural_Formulae_V.1.svg?width=300.
- Q2014070 wikiPageWikiLink Q14902045.
- Q2014070 wikiPageWikiLink Q165328.
- Q2014070 wikiPageWikiLink Q247489.
- Q2014070 wikiPageWikiLink Q30612.
- Q2014070 wikiPageWikiLink Q427492.
- Q2014070 wikiPageWikiLink Q4941581.
- Q2014070 wikiPageWikiLink Q52376.
- Q2014070 wikiPageWikiLink Q8047.
- Q2014070 wikiPageWikiLink Q824258.
- Q2014070 wikiPageWikiLink Q8431759.
- Q2014070 wikiPageWikiLink Q848085.
- Q2014070 atcPrefix "none".
- Q2014070 casNumber "603139".
- Q2014070 iupacName "N--4-fluoro-N2-{-2,2,2-trifluoro-1-[4'-biphenyl-4-yl]ethyl}-(L)-leucinamide".
- Q2014070 pubchem "10152654".
- Q2014070 unii "N673F6W2VH".
- Q2014070 type ChemicalSubstance.
- Q2014070 type Drug.
- Q2014070 type ChemicalObject.
- Q2014070 type Thing.
- Q2014070 type Q8386.
- Q2014070 comment "Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015, but as of early 2016 there was no report of any application.".
- Q2014070 label "Odanacatib".
- Q2014070 depiction Odanacatib_Structural_Formulae_V.1.svg.